Pharma IQ Members

Roger
Humphrey

Roger 2

Executive Managing Director and leader of Life Sciences practice,

JLL


Roger Humphrey is Executive Managing Director of the Life Sciences practice at JLL, where he guides a team of more than 2,200 professionals that help pharmaceutical and biotech companies reduce costs and boost productivity throughout their real estate and facilities portfolios. 

A leader in the real estate industry for more than 30 years, Humphrey is the former executive director, global real estate and integrated facilities management (IFM) governance, at Merck & Co. Inc., where his team managed a 100-million-square-foot portfolio spanning 750 sites in 80 countries, created Merck's global IFM outsourcing program and led facilities integration during Merck's merger with Schering-Plough. Humphrey holds an MBA from Babson College and a BSBA with a concentration in finance from Northeastern University, as well as Master of Corporate Real Estate (MCR) and Senior Leader of Corporate Real Estate (SLCR) designations from CoreNet Global, the leading corporate real estate association.

Frustrated by the fight for prime lab space in the US, life sciences companies are exploring the surrounding suburbs of major clusters for more affordable research facilities.
Tags:
Opportunity almost always comes with risk—and that's especially true for life sciences companies looking at new markets for new value. While globalization can be a means for driving value, JLL’s Life Sciences Outlook calls it a "high risk" strategy from a real estate and facilities perspective. In this Q... Read more
Tags:
Are you a life science company looking for change management best practices to transform your culture. Ready to overcome the excuses and speed up progress? Following these five steps to engagement-oriented change management strategy.
Science says sunshine and greenery reduce researcher stress, increase productivity Are you looking for the elusive keys to innovation and productivity? Take a closer look at that potted plant in your windowsill.
Following the “gloom and doom” of the patent cliff, 2014 has been a refreshing year. Replacing the focus on patent expirations, depleted product pipelines and uncertainty in U.S. healthcare reform, 2014 brought a noticeable resurgence of economic activity and positive growth to the life sciences industry. In particular, small to medium-sized... Read more
Biotechnology and pharmaceutical companies, including small and mid-size firms, can learn from Merck’s experience by using three primary strategies.
With the market for biologic and biosimilar medicines growing rapidly, traditional pharmaceutical manufacturing facilities and facilities management practices are fast becoming obsolete. Where small-molecule production facilities are relatively easy to transition from production of one drug to another, transitioning to biologics production is a... Read more